This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

USPTO session features debates about PTAB value for life sciences patents

By Nick Robertson ( March 31, 2026, 20:14 GMT | Insight) -- Advocates for the pharmaceutical industry argued at a US Patent and Trademark Office event Monday that inter partes review challenges at the Patent Trial and Appeal Board are duplicative and unnecessary, while representatives of generic and biosimilar called the board a “vital tool” to enable drug access and market competition.The US Patent and Trademark Office’s first listening session about the Patent Trial and Appeal Board on Monday centered on a debate over whether the board is a necessary and effective forum for patent challenges in the life sciences space. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections